Why choose Embryo46 as your new PGT-A solution?
Increased Success Rates
Higher Detection Resolution
Uniparental Disomy (UPD) Detection
Ploidy Status (PN Check)
Higher Detection Resolution
Embryo46 provides enhanced sequencing resolution that can better detect smaller CNV fragments for chromosomal abnormalities. This allows for the selection of embryos that can result in higher pregnancy rates and fewer genetic defects.
Ploidy Status
Unlike traditional PGT-A, Embryo46 also detects haploidy (one set of chromosomes) and triploidy (three sets of chromosomes), which have been shown to cause over 15-18% of miscarriages (Mutia K, et al. 2019). Selecting embryos with correct sets of chromosomes (diploidy) increases successful pregnancy rates while reducing the risk of genetic abnormalities.
Uniparental Disomy (UPD) Detection
UPD occurs in approximately .05% of newborns, where both sets of chromosomes are inherited from a single parent. This can lead to various imprinted genetic disorders, including Angelman syndrome and Prader-Willi syndrome.
Improving Patient Outcomes
A recent study has shown that our PGT-A test, Embryo46, led to higher successful pregnancy rates, higher live birth rates, and lower miscarriage rates.
Who is Embryo46 for?
Preimplantation genetic testing can be beneficial for any IVF patient, but patients who meet one or more of the following conditions have the most to gain from Embryo46:
- Women aged 35+ (risk of chromosomal abnormalities increases with age)
- History of implantation failure
- History of miscarriage
- History of failed IVF cycle with good quality embryos tested with traditional PGT-A
Contact Us
Do you have more questions? Curious about how Embryo46 can increase your clinic’s success rate?
Head over to our Contact page, or set up a learning session with our Global Business Development Director Tiffany Wang by reaching out directly at: tiffany@intilabs.com
References
Ariad D, Yan SM, Victor AR, et al. Haplotype-aware inference of human chromosome abnormalities. Proc Natl Acad Sci U S A. 2021;118(46):e2109307118. doi:10.1073/pnas.2109307118
Dong Y, Liu D, Zou Y, et al. Preimplantation genetic testing for human blastocysts with potential parental contamination using a quantitative parental contamination test (qPCT): an evidence-based study. Reprod Biomed Online. 2023;46(1):69-79. doi:10.1016/j.rbmo.2022.08.103
Gao FF, Chen L, Bo SP, et al. ChromInst: A single cell sequencing technique to accomplish pre-implantation comprehensive chromosomal screening overnight. PLoS One. 2021;16(5):e0251971. Published 2021 May 20. doi:10.1371/journal.pone.0251971
Huang J, Yan L, Lu S, Zhao N, Xie XS, Qiao J. Validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of blastocysts. Fertil Steril. 2016;105(6):1532-1536. doi:10.1016/j.fertnstert.2016.01.040